Why the study?
How do physiologic changes associated with aging affect the pharmacokinetics and pharmacodynamics of anticancer therapies in older adults?
How do physiologic changes associated with aging affect the pharmacokinetics and pharmacodynamics of anticancer therapies in older adults?
This review highlights the need for further research on how aging-related physiologic changes impact the clinical pharmacology of cancer therapies.
Aging-related physiologic changes may alter anticancer drug handling; leaves open optimal dosing guidance for older adults pending targeted studies.
This abbreviated review outlines the physiologic changes associated with aging, and examines how these changes may affect the pharmacokinetics and pharmacodynamics of anticancer therapies. We also provide an overview of studies that have been conducted evaluating the pharmacology of anticancer therapies in older adults, and issue a call for further research.
No takes yet. Share an insight, caveat, or question.
Hurria et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: